Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data

Aim The management of type 2 diabetes mellitus has advanced in the last two decades since the introduction of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). However, multiple factors may interfere with achieving better glycaemic control. This study evaluated the differences between various GL...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2024-10, Vol.26 (10), p.4646-4652
Main Authors: Kassem, Sameer, Khalaila, Buthaina, Stein, Nili, Saliba, Walid, Zaina, Adnan
Format: Article
Language:English
Subjects:
Agonists
database research
Diabetes
Diabetes mellitus (non-insulin dependent)
Epidemiology
GLP-1 receptor agonists
Glucagon
glucagon‐like peptide‐1 analogue
glycaemic control
Hemoglobin
Patients
Peptides
real‐world evidence
type 2 diabetes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2438-9b0df29b60bc1b6ff22ca281fa77289add07544429a5ba9f50eeb1c657ab81be3
container_end_page 4652
container_issue 10
container_start_page 4646
container_title Diabetes, obesity & metabolism
container_volume 26
creator Kassem, Sameer
Khalaila, Buthaina
Stein, Nili
Saliba, Walid
Zaina, Adnan
description Aim The management of type 2 diabetes mellitus has advanced in the last two decades since the introduction of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). However, multiple factors may interfere with achieving better glycaemic control. This study evaluated the differences between various GLP‐1RAs in efficacy, adherence and persistence. Materials and Methods We conducted a retrospective cohort study using the electronic medical database from Clalit Health Services. Adults with type 2 diabetes mellitus who purchased any GLP‐1RA between 2009 and 2021 were included. The Index Date was defined as the date of the first purchase of any GLP‐1RA. We evaluated the adherence, persistence and glycaemic control after GLP‐1RAs initiation. Baseline glycaemic and post‐treatment glycaemic controls were analysed. Results In total, 70 654 patients were included. The mean age was 11.7 ± 60.4, and 51% were females. A significant reduction in glycated haemoglobin (HbA1c) was observed in all patients who received GLP‐1RAs. However, the percentage of changes in the HbA1c was higher among weekly GLP‐1RA than daily initiators (14.6% vs. 10.2%, p 
doi_str_mv 10.1111/dom.15828
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3089882211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3106342954</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2438-9b0df29b60bc1b6ff22ca281fa77289add07544429a5ba9f50eeb1c657ab81be3</originalsourceid><addsrcrecordid>eNp1kc9OHSEUxkmjUasu-gINiZs2cRSYf-CuubVqonHTrskBDhY7d2YKMzV310foM_ZJxHttFyayORz4nY9z-Ah5x9kJz-vUDcsTXksh35A9XjVlwUvRbK33opCKiV3yNqV7xlhVynaH7JaKM1XV9R4Zz70PFuzqmIL7jhF7ixR6R0eMKaRpnQ-e_oIYhjnRu262cDf0f3__6cIPzNg4BYc55fTpPJekM9rDFIb-IV_QiNCtYY_UwQQHZNtDl_DwOe6Tb1_Ovy4ui-vbi6vFp-vCitxkoQxzXijTMGO5abwXwoKQ3EPbCqnAOdbWVVUJBbUB5WuGaLht6haM5AbLffJhozvG4eeMadLLkCx2HfSYB9Elk0pKITjP6NEL9H6YY5-70yVnTZkfqatMfdxQNg4pRfR6jGEJcaU500826GyDXtuQ2ffPirNZovtP_vv3DJxugIfQ4ep1Jf359mYj-QigppUV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106342954</pqid></control><display><type>article</type><title>Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kassem, Sameer ; Khalaila, Buthaina ; Stein, Nili ; Saliba, Walid ; Zaina, Adnan</creator><creatorcontrib>Kassem, Sameer ; Khalaila, Buthaina ; Stein, Nili ; Saliba, Walid ; Zaina, Adnan</creatorcontrib><description>Aim The management of type 2 diabetes mellitus has advanced in the last two decades since the introduction of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). However, multiple factors may interfere with achieving better glycaemic control. This study evaluated the differences between various GLP‐1RAs in efficacy, adherence and persistence. Materials and Methods We conducted a retrospective cohort study using the electronic medical database from Clalit Health Services. Adults with type 2 diabetes mellitus who purchased any GLP‐1RA between 2009 and 2021 were included. The Index Date was defined as the date of the first purchase of any GLP‐1RA. We evaluated the adherence, persistence and glycaemic control after GLP‐1RAs initiation. Baseline glycaemic and post‐treatment glycaemic controls were analysed. Results In total, 70 654 patients were included. The mean age was 11.7 ± 60.4, and 51% were females. A significant reduction in glycated haemoglobin (HbA1c) was observed in all patients who received GLP‐1RAs. However, the percentage of changes in the HbA1c was higher among weekly GLP‐1RA than daily initiators (14.6% vs. 10.2%, p &lt; 0.001). The proportion of subjects with any decrease in HbA1c was higher among the once‐weekly compared with the daily dose (82.4% vs. 74.7%) and mainly patients initiated semaglutide or dulaglutide, with 16.0% and 14.7% reduction. The frequency of good adherence (the proportion of days covered ≥80%) was significantly higher among the weekly group odds ratio = 1.25 (95% confidence interval 1.21–1.28). Good adherence was reported in older age, female gender, Jewish ethnicity and high socio‐economic status (p &lt; 0.001). Conclusions Weekly GLP‐1RAs initiators were more adherent, persistent to therapy and achieved better glycaemic control. Epidemiological variables might play a role in achieving this goal.</description><identifier>ISSN: 1462-8902</identifier><identifier>ISSN: 1463-1326</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.15828</identifier><identifier>PMID: 39109455</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Agonists ; database research ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Epidemiology ; GLP-1 receptor agonists ; Glucagon ; glucagon‐like peptide‐1 analogue ; glycaemic control ; Hemoglobin ; Patients ; Peptides ; real‐world evidence ; type 2 diabetes</subject><ispartof>Diabetes, obesity &amp; metabolism, 2024-10, Vol.26 (10), p.4646-4652</ispartof><rights>2024 The Author(s). published by John Wiley &amp; Sons Ltd.</rights><rights>2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley &amp; Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2438-9b0df29b60bc1b6ff22ca281fa77289add07544429a5ba9f50eeb1c657ab81be3</cites><orcidid>0000-0001-7482-3104</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39109455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kassem, Sameer</creatorcontrib><creatorcontrib>Khalaila, Buthaina</creatorcontrib><creatorcontrib>Stein, Nili</creatorcontrib><creatorcontrib>Saliba, Walid</creatorcontrib><creatorcontrib>Zaina, Adnan</creatorcontrib><title>Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data</title><title>Diabetes, obesity &amp; metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aim The management of type 2 diabetes mellitus has advanced in the last two decades since the introduction of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). However, multiple factors may interfere with achieving better glycaemic control. This study evaluated the differences between various GLP‐1RAs in efficacy, adherence and persistence. Materials and Methods We conducted a retrospective cohort study using the electronic medical database from Clalit Health Services. Adults with type 2 diabetes mellitus who purchased any GLP‐1RA between 2009 and 2021 were included. The Index Date was defined as the date of the first purchase of any GLP‐1RA. We evaluated the adherence, persistence and glycaemic control after GLP‐1RAs initiation. Baseline glycaemic and post‐treatment glycaemic controls were analysed. Results In total, 70 654 patients were included. The mean age was 11.7 ± 60.4, and 51% were females. A significant reduction in glycated haemoglobin (HbA1c) was observed in all patients who received GLP‐1RAs. However, the percentage of changes in the HbA1c was higher among weekly GLP‐1RA than daily initiators (14.6% vs. 10.2%, p &lt; 0.001). The proportion of subjects with any decrease in HbA1c was higher among the once‐weekly compared with the daily dose (82.4% vs. 74.7%) and mainly patients initiated semaglutide or dulaglutide, with 16.0% and 14.7% reduction. The frequency of good adherence (the proportion of days covered ≥80%) was significantly higher among the weekly group odds ratio = 1.25 (95% confidence interval 1.21–1.28). Good adherence was reported in older age, female gender, Jewish ethnicity and high socio‐economic status (p &lt; 0.001). Conclusions Weekly GLP‐1RAs initiators were more adherent, persistent to therapy and achieved better glycaemic control. Epidemiological variables might play a role in achieving this goal.</description><subject>Agonists</subject><subject>database research</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Epidemiology</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>glucagon‐like peptide‐1 analogue</subject><subject>glycaemic control</subject><subject>Hemoglobin</subject><subject>Patients</subject><subject>Peptides</subject><subject>real‐world evidence</subject><subject>type 2 diabetes</subject><issn>1462-8902</issn><issn>1463-1326</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc9OHSEUxkmjUasu-gINiZs2cRSYf-CuubVqonHTrskBDhY7d2YKMzV310foM_ZJxHttFyayORz4nY9z-Ah5x9kJz-vUDcsTXksh35A9XjVlwUvRbK33opCKiV3yNqV7xlhVynaH7JaKM1XV9R4Zz70PFuzqmIL7jhF7ixR6R0eMKaRpnQ-e_oIYhjnRu262cDf0f3__6cIPzNg4BYc55fTpPJekM9rDFIb-IV_QiNCtYY_UwQQHZNtDl_DwOe6Tb1_Ovy4ui-vbi6vFp-vCitxkoQxzXijTMGO5abwXwoKQ3EPbCqnAOdbWVVUJBbUB5WuGaLht6haM5AbLffJhozvG4eeMadLLkCx2HfSYB9Elk0pKITjP6NEL9H6YY5-70yVnTZkfqatMfdxQNg4pRfR6jGEJcaU500826GyDXtuQ2ffPirNZovtP_vv3DJxugIfQ4ep1Jf359mYj-QigppUV</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Kassem, Sameer</creator><creator>Khalaila, Buthaina</creator><creator>Stein, Nili</creator><creator>Saliba, Walid</creator><creator>Zaina, Adnan</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7482-3104</orcidid></search><sort><creationdate>202410</creationdate><title>Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data</title><author>Kassem, Sameer ; Khalaila, Buthaina ; Stein, Nili ; Saliba, Walid ; Zaina, Adnan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2438-9b0df29b60bc1b6ff22ca281fa77289add07544429a5ba9f50eeb1c657ab81be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Agonists</topic><topic>database research</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Epidemiology</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>glucagon‐like peptide‐1 analogue</topic><topic>glycaemic control</topic><topic>Hemoglobin</topic><topic>Patients</topic><topic>Peptides</topic><topic>real‐world evidence</topic><topic>type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kassem, Sameer</creatorcontrib><creatorcontrib>Khalaila, Buthaina</creatorcontrib><creatorcontrib>Stein, Nili</creatorcontrib><creatorcontrib>Saliba, Walid</creatorcontrib><creatorcontrib>Zaina, Adnan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity &amp; metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kassem, Sameer</au><au>Khalaila, Buthaina</au><au>Stein, Nili</au><au>Saliba, Walid</au><au>Zaina, Adnan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data</atitle><jtitle>Diabetes, obesity &amp; metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2024-10</date><risdate>2024</risdate><volume>26</volume><issue>10</issue><spage>4646</spage><epage>4652</epage><pages>4646-4652</pages><issn>1462-8902</issn><issn>1463-1326</issn><eissn>1463-1326</eissn><abstract>Aim The management of type 2 diabetes mellitus has advanced in the last two decades since the introduction of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). However, multiple factors may interfere with achieving better glycaemic control. This study evaluated the differences between various GLP‐1RAs in efficacy, adherence and persistence. Materials and Methods We conducted a retrospective cohort study using the electronic medical database from Clalit Health Services. Adults with type 2 diabetes mellitus who purchased any GLP‐1RA between 2009 and 2021 were included. The Index Date was defined as the date of the first purchase of any GLP‐1RA. We evaluated the adherence, persistence and glycaemic control after GLP‐1RAs initiation. Baseline glycaemic and post‐treatment glycaemic controls were analysed. Results In total, 70 654 patients were included. The mean age was 11.7 ± 60.4, and 51% were females. A significant reduction in glycated haemoglobin (HbA1c) was observed in all patients who received GLP‐1RAs. However, the percentage of changes in the HbA1c was higher among weekly GLP‐1RA than daily initiators (14.6% vs. 10.2%, p &lt; 0.001). The proportion of subjects with any decrease in HbA1c was higher among the once‐weekly compared with the daily dose (82.4% vs. 74.7%) and mainly patients initiated semaglutide or dulaglutide, with 16.0% and 14.7% reduction. The frequency of good adherence (the proportion of days covered ≥80%) was significantly higher among the weekly group odds ratio = 1.25 (95% confidence interval 1.21–1.28). Good adherence was reported in older age, female gender, Jewish ethnicity and high socio‐economic status (p &lt; 0.001). Conclusions Weekly GLP‐1RAs initiators were more adherent, persistent to therapy and achieved better glycaemic control. Epidemiological variables might play a role in achieving this goal.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>39109455</pmid><doi>10.1111/dom.15828</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7482-3104</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-8902
ispartof Diabetes, obesity & metabolism, 2024-10, Vol.26 (10), p.4646-4652
issn 1462-8902
1463-1326
1463-1326
language eng
recordid cdi_proquest_miscellaneous_3089882211
source Wiley-Blackwell Read & Publish Collection
subjects Agonists
database research
Diabetes
Diabetes mellitus (non-insulin dependent)
Epidemiology
GLP-1 receptor agonists
Glucagon
glucagon‐like peptide‐1 analogue
glycaemic control
Hemoglobin
Patients
Peptides
real‐world evidence
type 2 diabetes
title Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy,%20adherence%20and%20persistence%20of%20various%20glucagon%E2%80%90like%20peptide%E2%80%901%20agonists:%20nationwide%20real%E2%80%90life%20data&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Kassem,%20Sameer&rft.date=2024-10&rft.volume=26&rft.issue=10&rft.spage=4646&rft.epage=4652&rft.pages=4646-4652&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.15828&rft_dat=%3Cproquest_cross%3E3106342954%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2438-9b0df29b60bc1b6ff22ca281fa77289add07544429a5ba9f50eeb1c657ab81be3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3106342954&rft_id=info:pmid/39109455&rfr_iscdi=true